{"title":"GLP-1受体激动剂：新的治疗前沿","authors":"","doi":"10.1038/s44220-025-00402-w","DOIUrl":null,"url":null,"abstract":"Given the early success of treating diabetes and obesity with glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their neurobiological effects, interest is mounting in identifying new clinical applications and repurposing of these drugs for the treatment of neuropsychiatric conditions. A growing body of evidence points to the potential of GLP-1RA medications for the treatment of specific mental disorders, which will open the door for continued development and refinement of this class of drugs.","PeriodicalId":74247,"journal":{"name":"Nature mental health","volume":"3 3","pages":"267-268"},"PeriodicalIF":8.7000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44220-025-00402-w.pdf","citationCount":"0","resultStr":"{\"title\":\"GLP-1 receptor agonists: new treatment frontiers\",\"authors\":\"\",\"doi\":\"10.1038/s44220-025-00402-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Given the early success of treating diabetes and obesity with glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their neurobiological effects, interest is mounting in identifying new clinical applications and repurposing of these drugs for the treatment of neuropsychiatric conditions. A growing body of evidence points to the potential of GLP-1RA medications for the treatment of specific mental disorders, which will open the door for continued development and refinement of this class of drugs.\",\"PeriodicalId\":74247,\"journal\":{\"name\":\"Nature mental health\",\"volume\":\"3 3\",\"pages\":\"267-268\"},\"PeriodicalIF\":8.7000,\"publicationDate\":\"2025-03-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.nature.com/articles/s44220-025-00402-w.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature mental health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.nature.com/articles/s44220-025-00402-w\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature mental health","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s44220-025-00402-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Given the early success of treating diabetes and obesity with glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their neurobiological effects, interest is mounting in identifying new clinical applications and repurposing of these drugs for the treatment of neuropsychiatric conditions. A growing body of evidence points to the potential of GLP-1RA medications for the treatment of specific mental disorders, which will open the door for continued development and refinement of this class of drugs.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
